VistaGen Therapeutics, Inc. Uncategorized Contracts & Agreements

Exclusive Negotiation Agreement by and between Fuji Pharma Co., Ltd. and Vistagen Therapeutics, Inc., dated September 1, 2023 (Filed With SEC on September 8, 2023)

Open Market Sale AgreementSM, dated May 14, 2021, by and between VistaGen Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 14, 2021)

Option Agreement, by and between VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc., dated September 11, 2018 (Filed With SEC on September 13, 2018)

EXCLUSIVE LICENSEAND SUBLICENSE AGREEMENT by andbetween VISTAGENTHERAPEUTICS, INC. and APOLLOBIOLOGICS LP EXCLUSIVE LICENSEAND SUBLICENSE AGREEMENT (Filed With SEC on February 13, 2017)

R E C I T A L S : (Filed With SEC on November 14, 2016)

VistaGen Therapeutics, Inc. (Filed With SEC on May 16, 2016)

AGREEMENT (Filed With SEC on May 13, 2015)

ACKNOWLEDGEMENT AND AGREEMENT (Filed With SEC on May 13, 2015)

AMENDMENT NO. 2 (Filed With SEC on October 3, 2014)

SUBSCRIPTIONAGREEMENT UNITS (Filed With SEC on June 25, 2014)

VISTAGEN THERAPEUTICS, INC. (Filed With SEC on April 8, 2014)

ASSIGNMENTANDASSUMPTION AGREEMENT (Filed With SEC on July 18, 2013)

NEGATIVE COVENANT AGREEMENT (Filed With SEC on October 16, 2012)

Notice of Award (Filed With SEC on December 20, 2011)

SIGN AND RETURN THIS PAGE TO CIRMRT1-01012-1 NOTICE OF GRANT AWARD CIRM RFA-08-02:Tools & Technologies California Institute for Regenerative Medicine (Filed With SEC on December 20, 2011)

VISTAGEN THERAPEUTICS, INC. (Filed With SEC on May 16, 2011)

WITNESSETH: (Filed With SEC on May 16, 2011)

Shawn K. Singh, JD Chief Executive Officer VistaGen Therapeutics, Inc. 384 Oyster Point Blvd., No. 8 South San Francisco, CA 94080 (650) 244-9997 ext. 224 ssingh@vistagen.com (Filed With SEC on May 16, 2011)

CLINICAL STUDY AGREEMENT IND 75,807 AV-101 (Filed With SEC on May 16, 2011)

VISTAGEN THERAPEUTICS, INC. CONVERSION AGREEMENT (Filed With SEC on May 16, 2011)